1. 2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study. (September 2015) Authors: Hsu, C.; Lee, S.H.; Ejadi, S.; Even, C.; Cohen, R.; Le Tourneau, C.; Mehnert, J.; Algazi, A.; Van Brummelen, E.; Yuan, S.S.; Thanigaimani, P.; Cheng, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. Issue 3 (September 2015) Authors: Ott, P.A.; Piha-Paul, S.A.; Munster, P.; Pishvaian, M.J.; Van Brummelen, E.; Cohen, R.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; Yuan, S.S.; Koshiji, M.; Bennouna, J. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine. (September 2015) Authors: Tabernero, J.; Homicsko, K.; Schellens, J.H.; Hoekstra, O.; Van der Veen, L.; Melero, I.; és, G. Argil; Mau-Sorensen, M.; Angevin, E.; Joensuu, H.; Van Brummelen, E.; van Oordt, C.W. Menke-van der Houven; Nayak, T.; Romagnoli, S.; Reis, B.; Brossard, S. Soehrman; Evers, S.; Saro, J.; Verheul, H.;... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗